Molecular biology of endotoxin antagonism

World Journal of Surgery

Volumn 26, Issue 7, 2002, Pages 790-798

  Lazaron, Victor ^a   Dunn, David L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTOXIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; PEPTIDE; CARRIER PROTEIN; LIPOPOLYSACCHARIDE;

BACTERIAL INFECTION; BIOCHEMISTRY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTOXEMIA; GRAM NEGATIVE BACTERIUM; MEDICAL RESEARCH; MOLECULAR BIOLOGY; PROTEIN ANALYSIS; SEPSIS; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MICROBIOLOGY; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; CARRIER PROTEINS; ENDOTOXEMIA; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MOLECULAR BIOLOGY; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036631561     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-002-4054-4     Document Type: Conference Paper

References (96)

1. Dunn DL. Gram-negative bacterial sepsis and sepsis syndrome. Surg. Clin. North Am. 1994;74:621-635
2. Rietschel ET, Schade U, Jensen M, et al. Bacterial endotoxins: chemical structure, biological activity and role in septicaemia. Scand. J. Infect. Dis. Suppl. 1982;31:8-21
3. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu. Rev. Med. 1987;38:417-432
4. Kotani S, Takada H, Tsujimoto M, et al. Immunobiological activities of synthetic lipid A analogs and related compounds as compared with those of bacterial lipopolysaccharide, re-glycolipid, lipid A, and muramyl dipeptide. Infect. Immun. 1983;41:758-766
5. Takada H, Kotani S. Structural requirements of lipid A for endotoxicity and other biological activities. CRC Crit. Rev. Microbiol. 1989;16:477-487
6. Kitchens RL, Munford RS. Enzymatically deacylated lipopolysaccharide (LPS) can antagonize LPS at multiple sites in the LPS recognition pathway. J. Biol. Chem. 1995;270:9904-9910
7. Jarvis BW, Lichenstein H, Qureshi N. Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS. Infect. Immun. 1997;65:3011-3016
8. Golenbock DT, Hampton RY, Qureshi N, et al. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J. Biol. Chem. 1991;266:19490-19498
9. Tobias P, Soldau K, Ulevitch R. Isolation of a lipopolysacharide-binding acute phase reactant from rabbit serum. J. Exp. Med. 1986;164:777-793
10. Calvano SE, Thompson WA, Marra MN, et al. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch. Surg. 1994;129:220-226
11. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990;249:1429-1433
12. Corradin SB, Mauel J, Gallay P, et al. Enhancement of murine macrophage binding of and response to bacterial lipopolysaccharide (LPS) by LPS-binding protein. J. Leukoc. Biol. 1992;52:363-368
13. Wright SD, Ramos RA, Tobias PS, et al. CD14 serves as the cellular receptor for complexes of lipopolysaccharide with lipopolysaccharide-binding protein. Science 1990;249:1431-1433
14. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997;389:742-745
15. Lamping N, Dettmer R, Schroder NW, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J. Clin. Invest. 1998;101:2065-2071
16. Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J. Biol. Chem. 1988;263:13479-13481
17. Gray PW, Flaggs G, Leong SR, et al. Cloning of the cDNA of a human neutrophil bactericidal protein: structure and functional correlations. J. Biol. Chem. 1989;264:9505-9509
18. Day JR, Albers JJ, Lofton-Day CE, et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J. Biol. Chem. 1994;269:9388-9391
19. Weiss J, Elsbach P, Olsson I, et al. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J. Biol. Chem. 1978;253:2664-2672
20. Elsbach P, Weiss J, Franson RC, et al. Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes: observations on their relationship. J. Biol. Chem. 1979;254:11000-11009
21. Hovde CJ, Gray BH. Physiological effects of a bactericidal protein from human polymorphonuclear leukocytes on Pseudomonas aeruginosa. Infect. Immun. 1986;52:90-95
22. Gazzano-Santoro H, Meszaros K, Birr C, et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect. Immun. 1994;62:1185-1191
23. Gray BH, Haseman JR. Bactericidal activity of synthetic peptides based on the structure of the 55-kilodalton bactericidal protein from human neutrophils. Infect. Immun. 1994;62:1732-1739
24. Hoess A, Watson S, Siber GR, et al. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 Å resolution. EMBO J. 1993;12:3351-3356
25. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997;276:1861-1864
26. Bowie JU, Zhang K, Wilmanns M, et al. Three-dimensional profiles for measuring compatibility of amino acid sequence with three-dimensional structure. Methods Enzymol. 1996;266:598-616
27. Webster CJ. Principles of a quantitative assay for bacterial endotoxins in blood that uses Limulus lysate and a chromogenic substrate. J. Clin. Microbiol. 1980;12:644-650
28. Tanaka S, Nakamura T, Morita T, et al. Limulus anti-LPS factor: an anticoagulant which inhibits the endotoxin mediated activation of Limulus coagulation system. Biochem. Biophys. Res. Commun. 1982;105:717-723
29. Morita T, Ohtsubo S, Nakamura T, et al. Isolation and biological activities of limulus anticoagulant (anti-LPS factor) which interacts with lipopolysaccharide (LPS). J. Biochem. (Tokyo) 1985;97:1611-1620
30. Aketagawa J, Miyata T, Ohtsubo S, et al. Primary structure of Limulus anticoagulant anti-lipopolysaccharide factor. J. Biol. Chem. 1986;261:7357-7365
31. Warren HS, Glennon ML, Wainwright N, et al. Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor. Infect. Immun. 1992;60:2506-2513
32. Fletcher MA, McKenna TM, Quance JL, et al. Lipopolysaccharide detoxification by endotoxin neutralizing protein. J. Surg. Res. 1993;55:147-154
33. Battafarano RJ, Dahlberg PS, Ratz CA, et al. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-α secretion in vitro. Surgery 1995;118:318-324
34. Ried C, Wahl C, Miethke T, et al. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor. J. Biol. Chem. 1996;271:28120-28127
35. Lee J-D Kato, K Tobias, PS, et al. Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J. Exp. Med. 1992;175:1697-1705
36. Frey EA, Miller DS, Jahr TG, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 1992;176:1665-1671
37. Pugin J, Schurer-Maly CC, Leturcq D, et al: Lipopolysaccharide (LPS) activation of human endothelial and epithelial cells is mediated by LPS binding protein and soluble CD14. Proc. Natl. Acad. Sci. U.S.A. 1993;90:2744-2748
38. Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996;4:407-414
39. Haziot A, Lin XY, Zhang F, et al. The induction of acute phase proteins by lipopolysaccharide uses a novel pathway that is CD14-independent. J. Immunol. 1998;160:2570-2572
40. Juan TS-C, Hailman E, Kelly MJ, et al. Identification of a lipopolysaccharide binding domain in CD14 between amino acids 57 and 64. J. Biol. Chem. 1995;270:5219-5224
41. McGinley MD, Narhi LO, Kelley MJ, et al. CD14: Physical properties and identification of an exposed site that is protected by lipopolysaccharide. J. Biol. Chem. 1995;270:5213-5218
42. Kirschning CJ, Wesche H, Ayres TM, et al. Human toll-like receptor 2 conveys responsiveness to bacterial lipopolysaccharide. J. Exp. Med. 1998;188:2091-2097
43. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature 1998;17:284-288
44. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088
45. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 1999;162:3749-3752
46. Muzio M, Natoli G, Saccani S, et al. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 1998;187:2097-2101
47. Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem. 1999;274:7611-7614
48. Dunn DL, Ferguson RM. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery 1982;92:212-219
49. Dunn DL, Bogard WC Jr, Cerra FB. Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. Arch. Surg. 1985;120:50-53
50. Dunn DL, Ewald DC, Chandan N, et al. Immunotherapy of gram-negative bacterial sepsis: a single murine monoclonal antibody provides cross-genera protection. Arch. Surg. 1986;121:58-62
51. Priest BP, Schlievert PM, Dunn DL. Treatment of toxic shock syndrome with endotoxin-neutralizing antibody. J. Surg. Res. 1989;46:527-531
52. Greenman RL, Schein RM, Martin MA, et al. A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. J.A.M.A. 1991;266:1097-1102
53. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical trial of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit. Care Med. 1995;23:994-1006
54. Baumgartner JD. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect. Dis. Clin. North Am. 1991;5:915-927
55. Warren HS, Amato SF, Fitting C, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 1993;177:89-97
56. McCabe W, Kreger B, Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N. Engl. J. Med. 1972;287:261-267
57. Zinner S, McCabe W. Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J. Infect. Dis. 1976;133:37-45
58. Goldie AS, Fearon KC, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome: the Sepsis Intervention Group. J.A.M.A. 1995;274:172-177
59. Strutz F, Heller G, Krasemann K, et al. Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med. 1999;25:435-444
60. Nys M, Damas P, Joassin L, et al. Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome. Ann. Surg. 1993;217:300-306
61. Di Padova FE, Brade H, Barclay GR, et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect. Immun. 1993;61:3863-3872
62. Barclay GR. Endotoxin-core antibodies: time for a reappraisal? Intensive Care Med. 1999;25:427-429
63. Kellogg TA, Weiss CA III, Johnston JW, et al. Antiendotoxin agents share molecular homology within their lipopolysaccharide binding domains. J. Surg. Res. 1999;85:136-141
64. Kuppermann N, Nelson DS, Saladino RA, et al. Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats. J. Infect. Dis. 1994;170:630-635
65. Garcia C, Saladino R, Thompson C, et al. Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits. Crit. Care Med. 1994;22:1211-1218
66. Roth RI, Su D, Child AH, et al. Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. J. Infect. Dis. 1998;177:388-394
67. Saladino RA, Stack AM, Thompson C, et al. High-dose recombinant endotoxin neutralizing protein improves survival in rabbits with Escherichia coli sepsis. Crit. Care Med. 1996;24:1203-1207
68. Weiner DL, Kuppermann N, Saladino RA, et al. Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis. Crit. Care Med. 1996;24:1514-1517
69. Theofan G, Horwitz AH, Williams RE, et al. An amino-terminal fragment of human lipopolysaccharide-binding protein retains lipid A binding but not CD14-stimulatory activity. J. Immunol. 1994;152:3623-3629
70. Han J, Mathison JC, Ulevitch RJ, et al. Lipopolysaccharide (LPS) binding protein, truncated at Ile-197, binds LPS but does not transfer LPS to CD14. J. Biol. Chem. 1994;269:8172-8175
71. Opal SM, Palardy JE, Jhung JW, et al. Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 1995;39:2813-2815
72. Jin H, Yang R, Marsters S, et al. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J. Clin. Invest. 1995;95:1947-1952
73. Fisher CJJ, Marra MN, Palardy JE, et al. Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study. Crit. Care Med. 1994;22:553-558
74. Marra MN, Thornton MB, Snable JL, et al. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit. Care Med. 1994;22:559-565
75. Ooi CE, Weiss J, Elsbach P, et al. A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J. Biol. Chem. 1987;262:14891-14894
76. Weiss J, Elsbach P, Shu C, et al. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J. Clin. Invest. 1992;90:1122-1130
77. Kohn FR, Ammons WS, Horwitz A, et al. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. J. Infect. Dis. 1993;168:1307-1310
78. Lin Y, Ammons WS, Leach WJ, et al. Protective effects of a recombinant N-terminal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. Shock 1994;2:324-331
79. Ammons WS, Kohn FR, Kung AH. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties. J. Infect. Dis. 1994;170:1473-1482
80. Lin Y, Leach WJ, Ammons WS. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrob. Agents Chemother. 1996;40:65-69
81. Lechner AJ, Lamprech KE, Johanns CA, et al. The recombinant 23-kDa N-terminal fragment of bactericidal/permeability-increasing protein (rBPI23) decreases Escherichia coli-induced mortality and organ injury during immunosuppression-related neutropenia. Shock 1995;4:298-306
82. Evans TJ, Carpenter A, Moyes D, et al. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. J. Infect. Dis. 1995;171:153-160
83. Bauer RJ, White ML, Wedel N, et al. A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock 1996;5:91-96
84. Giroir BP, Quint PA, Barton P, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997;350:1439-1443
85. Demetriades D, Smith JS, Jacobson LE, et al. Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group. J. Trauma 1999;46:667-676
86. De Haas CJ, Haas PJ, van Kessel KP, et al. Affinities of different proteins and peptides for lipopolysaccharide as determined by biosensor technology. Biochem. Biophys. Res. Commun. 1998;252:492-496
87. Mayo KH, Haseman J, Ilyina E, et al. Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. Biochim. Biophys. Acta 1998;1425:81-92
88. Uknis ME, Wasiluk KR, Acton RD, et al. Design of a potent novel endotoxin antagonist. Surgery 1997;122:380-385
89. Dahlberg PS, Acton RD, Battafarano RJ, et al. A novel endotoxin antagonist attenuates tumor necrosis factor-alpha secretion. J. Surg. Res. 1996;63:44-48
90. Dahlberg PS, Acton RD, Uknis ME, et al. Macrophages expressing a fusion protein derived from bactericidal/permeability-increasing protein and IgG are resistant to endotoxin. Arch. Surg. 1996;131:1173-1177
91. Gray BH, Haseman JR, Mayo KH. B/PI-derived synthetic peptides: synergistic effects in tethered bactericidal and endotoxin neutralizing peptides. Biochim. Biophys. Acta 1995;1244:185-190
92. Gallay P, Heumann D, Le Roy D, et al. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc. Natl. Acad. Sci. U.S.A. 1993;90:9935-9938
93. Gallay P, Heumann D, Le Roy D, et al. Mode of action of antilipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc. Natl. Acad. Sci. U.S.A. 1994;91:7922-7926
94. Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J. Infect. Dis. 1999;180:1584-1589
95. Schimke J, Mathison J, Morgiewicz J, et al. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. U.S.A. 1998;95:13875-13880
96. Leturcq DJ, Moriarty AM, Talbott G, et al. Antibodies against CD14 protect primates from endotoxin-induced shock. J. Clin. Invest. 1996;98:1533-1538